alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
[Federal Register Volume 75, Number 44 (Monday, March 8, 2010)]
[Notices]
[Page 10505]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4744]


-----------------------------------------------------------------------

DEPARTMENT OF LABOR

Employment and Training Administration

[TA-W-73,157]


FCI USA, LLC, Including On-Site Leased Workers From Manpower, 
Inc., Mount Union, PA; Amended Certification Regarding Eligibility To 
Apply for Worker Adjustment Assistance

    In accordance with Section 223 of the Trade Act of 1974, as amended 
(``Act''), 19 U.S.C. 2273, the Department of Labor issued a 
Certification of Eligibility to Apply for Worker Adjustment Assistance 
on January 22, 2010, applicable to workers of FCI USA, LLC, including 
on-site leased workers from Manpower, Inc., Mount Union, Pennsylvania. 
The notice will be published soon in the Federal Register.
    At the request of the State Agency, the Department reviewed the 
certification for workers of the subject firm. The workers are engaged 
in activities related to the production of electrical components for 
various communications devices, personal computers, and auto 
dashboards.
    The review shows that on February 21, 2008, a certification of 
eligibility to apply for adjustment assistance was issued for all 
workers of FCI USA, Inc., Mount Union, Pennsylvania, separated from 
employment on or after September 28, 2007 through February 21, 2010. 
The notice was published in the Federal Register on March 7, 2008 (73 
FR 12466).
    In order to avoid an overlap in worker group coverage, the 
Department is amending the December 22, 2008 impact date established 
for TA-W-73,157, to read February 22, 2010.
    The amended notice applicable to TA-W-73,157 is hereby issued as 
follows:

    All workers of FCI USA, LLC, including on-site leased workers 
from Manpower, Inc., Mount Union, Pennsylvania, who became totally 
or partially separated from employment on or after February 22, 
2010, through January 22, 2012, and all workers in the group 
threatened with total or partial separation from employment on date 
of certification through two years from the date of certification, 
are eligible to apply for adjustment assistance under Chapter 2 of 
Title II of the Trade Act of 1974, as amended.

    Signed in Washington, DC, this 22nd day of February 2010.
Elliott S. Kushner,
Certifying Officer, Division of Trade Adjustment Assistance.
[FR Doc. 2010-4744 Filed 3-5-10; 8:45 am]
BILLING CODE 4510-FN-P
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

      ( print page 10293)    
Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute on Alcohol Abuse and Alcoholism, Initial Review Group Neuroscience Review Subcommittee.                    

*Date:*                         June 7-8, 2010.                    

*Time:*                         8 a.m. to 5 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road, NW., Washington, DC 20015.                    

*Contact Person:*                         Beata Buzas, PhD. Scientific Review Officer,  National Institute on Alcohol Abuse and Alcoholism,  National Institutes of Health,  5635 Fishers Lane, Rm 2081,  Rockville, MD 20852.  301-443-0800.                         *bbuzas@mail.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.271, Alcohol Research Career Development Awards for Scientists and Clinicians; 93.272, Alcohol National Research Service Awards for Research Training; 93.273, Alcohol Research Programs; 93.891, Alcohol Research Center Grants; 93.701, ARRA Related Biomedical Research and Research Support Awards, National Institutes of Health, HHS)

Dated: February 26, 2010.

Jennifer Spaeth,

Director, Office Federal Advisory Committee Policy.

[FR Doc. 2010-4587 Filed 3-4-10; 8:45 am]

BILLING CODE 4140-01-M
##### 



Exhibit 13.1 CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Deswell Industries, Inc. (the Company) on Form 20-F for
the year ended March 31, 2005 as filed with the Securities and Exchange Commission on the date
hereof (the Report), the undersigned hereby certify, pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of our knowledge,
that: (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and (2) The information contained in the Report fairly presents, in all material respects, the
financial condition and results of operations of the Company. Date: July 8, 2005
    
    By:
    
    /s/ Richard LauRichard LauChief Executive OfficerDate: July 8, 2005
    
    By:
    
    /s/ C. P. LiC. P. LiChief Financial Officer
Editorial Note on Part 872
Editorial Note: Nomenclature changes to part 872 appear at 73 FR 35341, June 23, 2008.

§ 872.3420 Carboxymethylcellulose sodium and cationic polyacrylamide polymer denture adhesive. ( a ) *Identification.* A carboxymethylcellulose sodium and cationic polyacrylamide polymer denture adhesive is a device composed of carboxymethylcellulose sodium and cationic polyacrylamide polymer intended to be applied to the base of a denture before the denture is inserted in a patient's mouth to improve denture retention and comfort.
( b ) *Classification.* Class III.
( c ) *Date PMA or notice of completion of a PDP is required.* A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before December 26, 1996 for any carboxymethylcellulose sodium and cationic polyacrylamide polymer denture adhesive that was in commercial distribution before May 28, 1976, or that has, on or before December 26, 1996 been found to be substantially equivalent to a carboxymethylcellulose sodium and cationic polyacrylamide polymer denture adhesive that was in commercial distribution before May 28, 1976. Any other carboxymethylcellulose sodium and cationic polyacrylamide polymer denture adhesive shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.
[52 FR 30097, Aug. 12, 1987, as amended at 61 FR 50707, Sept. 27, 1996]
§ 74.2327 D&C Red No. 27. ( a ) *Identity and specifications.* The color additive D&C Red No. 27 shall conform in identity and specifications to the requirements of § 74.1327 (a)(1) and (b).
( b ) *Uses and restrictions.* D&C Red No. 27 may be safely used for coloring cosmetics generally in amounts consistent with current good manufacturing practice.
( c ) *Labeling requirements.* The label of the color additive shall conform to the requirements of § 70.25 of this chapter.
( d ) *Certification.* All batches of D&C Red No. 27 shall be certified in accordance with regulations in part 80 of this chapter.
[47 FR 42568, Sept. 28, 1982]
<PAGE>
 
                                                                      EXHIBIT 11




                               THE BIBB COMPANY
                STATEMENT RE: COMPUTATION OF EARNINGS PER SHARE
                     (IN THOUSANDS, EXCEPT PER SHARE DATA)

<TABLE> 
<CAPTION> 
                                                         THREE MONTHS            THREE MONTHS
                                                             ENDED                  ENDED
                                                         APRIL 4, 1998          MARCH 29, 1997
                                                         -------------          --------------
<S>                                                      <C>                    <C> 
Net income (loss) applicable to common stock               $    111                $ (2,191)

Weighted average shares outstanding:

   Weighted average common shares outstanding                10,062                  10,062

   Shares upon assumed exercise of stock options (1)            120                       0
                                                           --------                --------
     Weighted average share outstanding                      10,182                  10,062
                                                           --------                --------
Diluted net income (loss) per share of common stock            0.01                   (0.22)
                                                           ========                ========
</TABLE> 
-----------

(1) Stock options are assumed exercised using the modified treasury stock
    method, except where the effect is anti-dilutive.
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the
Company's financial statements in the Company's Annual Report on Form 10-K for
the year ended December 31, 1997.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               DEC-31-1997
<CASH>                                       3,082,202
<SECURITIES>                                         0
<RECEIVABLES>                                8,365,467
<ALLOWANCES>                                 2,200,000
<INVENTORY>                                  5,163,682
<CURRENT-ASSETS>                            19,093,148
<PP&E>                                       2,320,061
<DEPRECIATION>                               1,512,489
<TOTAL-ASSETS>                              29,378,525
<CURRENT-LIABILITIES>                        7,327,784
<BONDS>                                     14,439,756
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         3,580
<OTHER-SE>                                   7,607,405
<TOTAL-LIABILITY-AND-EQUITY>                29,378,525
<SALES>                                     19,330,025
<TOTAL-REVENUES>                            20,530,376
<CGS>                                       12,887,283
<TOTAL-COSTS>                               12,887,283
<OTHER-EXPENSES>                            28,883,328
<LOSS-PROVISION>                             1,979,000
<INTEREST-EXPENSE>                             383,962
<INCOME-PRETAX>                           (21,278,452)
<INCOME-TAX>                               (2,694,447)
<INCOME-CONTINUING>                       (18,584,005)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                              (18,584,005)
<EPS-PRIMARY>                                   (2.60)
<EPS-DILUTED>                                   (2.60)
        

</TABLE>
*Product ingredient source information may be entitled to confidential treatment**Product ingredient source information may be entitled to confidential treatment*______________________________________________________________ Page is not included in this copy. Pages 82 through 83 are not included in this copy.

_________________________________________________________________ The material not included contains the following type of information: _____ Identity of product inert ingredients.

__ __ Identity of product impurities.

__ __ Description of the product manufacturing process.

__ __ Description of quality control procedures.

__ __ Identity of the source of product ingredients. _____ Sales or other commercial/financial information. _____ A draft product label. __X __ The product confidential statement of formula. _____ Information about a pending registration action.

__ __ FIFRA registration data.

__ __ The document is a duplicate of page(s) _ . _____ The document is not responsive to the request.

__ __ Internal deliberative information.

__ __ Privileged attorney-client communication.

__ __ Claimed Confidential by submitter upon submission to the Agency.
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1165 Catecholamines (total) test system. ( a ) *Identification.* A catecholamines (total) test system is a device intended to determine whether a group of similar compounds (epinephrine, norepinephrine, and dopamine) are present in urine and plasma. Catecholamine determinations are used in the diagnosis and treatment of adrenal medulla and hypertensive disorders, and for catecholamine-secreting tumors (pheochromo-cytoma, neuroblastoma, ganglioneuroma, and retinoblastoma).
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.
[52 FR 16122, May 1, 1987, as amended at 65 FR 2305, Jan. 14, 2000]
EXHIBIT 23.2

               CONSENT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANT

James Moore & Co., P.L. hereby consents to the incorporation by reference in
this Registration Statement on Form S-8 of R-Tec Technologies, Inc. (the
"Company") of our report dated May 7, 2001 on the consolidated financial
statements of the Company contained in the Company's annual report on Form 10-K
for the year ended December 30, 2000 and to references to our firm in such
Registration Statement.

October 11, 2001                                    James Moore & Co., P.L.
<TABLE> <S> <C>


<ARTICLE>                     5
<MULTIPLIER>                  1
<CURRENCY>                    U.S. Dollars               
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>               SEP-01-1999         
<PERIOD-START>                  OCT-01-1998   
<PERIOD-END>                    MAR-31-1999   
<EXCHANGE-RATE>                            1   
<CASH>                               145,471  
<SECURITIES>                               0   
<RECEIVABLES>                         16,425  
<ALLOWANCES>                               0  
<INVENTORY>                                0  
<CURRENT-ASSETS>                     161,896  
<PP&E>                               304,914  
<DEPRECIATION>                       130,324  
<TOTAL-ASSETS>                       336,486  
<CURRENT-LIABILITIES>                 46,392  
<BONDS>                                    0  
<PREFERRED-MANDATORY>                      0  
<PREFERRED>                                0  
<COMMON>                             122,146  
<OTHER-SE>                           141,753  
<TOTAL-LIABILITY-AND-EQUITY>         336,486  
<SALES>                                    0  
<TOTAL-REVENUES>                       6,000  
<CGS>                                      0  
<TOTAL-COSTS>                              0  
<OTHER-EXPENSES>                      14,532  
<LOSS-PROVISION>                           0  
<INTEREST-EXPENSE>                    (1,154)  
<INCOME-PRETAX>                       (7,378) 
<INCOME-TAX>                               0 
<INCOME-CONTINUING>                   (7,378)  
<DISCONTINUED>                       (11,178) 
<EXTRAORDINARY>                            0 
<CHANGES>                                  0  
<NET-INCOME>                         (18,556)  
<EPS-PRIMARY>                            .00 
<EPS-DILUTED>                            .00     
        


</TABLE>
### Ground-water hydrology of the Punjab region of West Pakistan, with emphasis on problems caused by canal irrigation

By: D.W. GreenmanW.V. SwarzenskiG.D. Bennett

                            https://doi.org/10.3133/wsp1608H

#### Links

-                                                                                                                             Document:                                                                                                                                                                                                                                                  **Report**                                                                                                     (pdf)                                                                                                                                     
- Plates:                               - **Plate 1**                            (pdf)
  - **Plate 2**                            (pdf)
  - **Plate 3**                            (pdf)
  - **Plate 4**                            (pdf)
  - **Plate 5**                            (pdf)
  - **Plate 6**                            (pdf)
  - **Plate 7**                            (pdf)
  - **Plate 8**                            (pdf)
  - **Plate 9**                            (pdf)
  - **Plate 10**                            (pdf) 
- Download citation as:  RIS                         |                         Dublin                            Core

#### Abstract

Part or all of this report is presented in Portable Document Format                        (PDF). For best results viewing and printing PDF documents, it is recommended that you download                        the documents to your computer and open them with Adobe Reader. PDF documents opened from your                        browser may not display or print as intended. Download the latest version of Adobe Reader, free of charge. More information                        about viewing, downloading, and printing report files can be found at the common download problems FAQ.
<TABLE> <S> <C>

<ARTICLE>                     5
<CIK>                         0000814576                        
<NAME>                        PAINEWEBBER R&D PARTNERS II, L.P.
                              
<S>                             <C>
<PERIOD-TYPE>                   9-MOS  
<FISCAL-YEAR-END>                            DEC-31-1997
<PERIOD-END>                                 SEP-30-1997
<CASH>                                             6,999  
<SECURITIES>                                   5,181,983
<RECEIVABLES>                                    892,545
<ALLOWANCES>                                           0
<INVENTORY>                                            0
<CURRENT-ASSETS>                               5,188,982
<PP&E>                                                 0
<DEPRECIATION>                                         0
<TOTAL-ASSETS>                                 6,081,527
<CURRENT-LIABILITIES>                            156,876
<BONDS>                                                0
<PREFERRED-MANDATORY>                                  0
<PREFERRED>                                            0
<COMMON>                                               0
<OTHER-SE>                                     5,924,651
<TOTAL-LIABILITY-AND-EQUITY>                   6,081,527
<SALES>                                                0
<TOTAL-REVENUES>                               8,535,614
<CGS>                                                  0
<TOTAL-COSTS>                                          0
<OTHER-EXPENSES>                                 243,091
<LOSS-PROVISION>                                       0
<INTEREST-EXPENSE>                                     0
<INCOME-PRETAX>                                8,292,523
<INCOME-TAX>                                           0
<INCOME-CONTINUING>                                    0
<DISCONTINUED>                                         0
<EXTRAORDINARY>                                        0
<CHANGES>                                              0
<NET-INCOME>                                   8,292,523
<EPS-PRIMARY>                                          0
<EPS-DILUTED>                                          0
        

</TABLE>
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7675 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7675

  To extend the authorization of appropriations for PFAS research and 
          development by the Environmental Protection Agency.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 13, 2024

 Mr. Pappas (for himself and Mr. Posey) introduced the following bill; 
  which was referred to the Committee on Energy and Commerce, and in 
   addition to the Committees on Science, Space, and Technology, and 
  Transportation and Infrastructure, for a period to be subsequently 
   determined by the Speaker, in each case for consideration of such 
 provisions as fall within the jurisdiction of the committee concerned

_______________________________________________________________________

                                 A BILL

 
  To extend the authorization of appropriations for PFAS research and 
          development by the Environmental Protection Agency.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``PFAS Research and Development 
Reauthorization Act of 2024''.

SEC. 2. AUTHORIZATION.

    Section 7362(b) of the National Defense Authorization Act for 
Fiscal Year 2020 (15 U.S.C. 8962(b)) is amended by striking ``2024'' 
and inserting ``2029''.
                                 <all>
```
Michigan Supreme Court Lansing, Michigan

Robert P. Young, Jr.,
Chief Justice

Michael F. Cavanag h Marilyn Kell y Stephen J. Markma n Diane M. Hathawa y Mary Beth Kell y Brian K. Zahra,
J ustices

I, Corbin R. Davis, Clerk of the Mi chigan Supreme Cour t, certify that the foregoing is a true and complete copy of the order entered at the direction of the Court.

_______________________________________ __ Clerk February 8, 2012 

# Order

February 8, 2012

143330(58)

PROGRESSIVE MARA THON INSURANCE COMPANY, Plaintiff/Cross-Defendant-Appellant, SC: 143330 v COA: 296502 Ottawa CC: 09-001034-CZ RYAN DEYOUNG and NICOLE L. DEYOUNG, Defendants,

and

SPECTRUM HEALTH HOSPITALS and MARY FREE BED REHABILITATION HOSPITAL, Intervenors/Cross-Plaintiffs-Appellees,

and

CITIZENS INSURANCE COMPANY OF AMERICA, Intervenor/Cross-Defendant-Appellee.

_____________ _______________ _____________

On order of the Chief Justic e, the motion by th e Insurance Institu te of Michigan
for leave to file a brief amicus curiae in this case is considered and it is granted.